Access Pharmaceuticals is an emerging biopharmaceutical company that develops and commercializes propriety products for the treatment and supportive care of cancer patients. Access ‘ products include ProLindac , currently online . In Phase II clinical testing of patients with ovarian cancer and MuGard for the treatment of patients with mucositis The company also has other advanced drug delivery technologies including vitamin-mediated targeted delivery and oral drug delivery. For more information on Access Pharmaceuticals, please visit our website.
Access Pharmaceuticals,in 2005, press releases side-by-side comparison of CARE Act Reauthorization ProposalsThe Ryan White CARE Act: A Side-by – side comparison of current law and reauthorization proposals, ‘Kaiser Family Foundation: publishes The Foundation on Tuesday a side – by-side comparison of the current Ryan White CARE Act and the amendments proposed by the Bush administration and in two congress bills the CARE Act. The largest federal program that paid for medical help medical care and other assistance to HIV-positive people and for the first time in 1990 in force – was the third time in 2005, Congress authorized are still debating the various reauthorization proposals that could change significantly, such as CARE Act funding will be distributed. The land are what. Services and how much control states and local jurisdictions on the financing decisions the comparison is available online and will be updated as soon as new developments occur was founded in 2005’Reprinted with permission, you can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at Kaiser Daily Health Policy Report is a free service for kaiser network of The Henry J. Kaiser. Family Foundation. In 2005 Advisory Board Company and Kaiser Family Foundation. All rights reserved. Continue reading